Skip to main content
Fig. 5 | Clinical Proteomics

Fig. 5

From: Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation

Fig. 5

A GO pathways enriched among plasma proteins that exhibited decreased expression in both non-ICU and ICU/F COVID-19 patient groups with respect to HDanalysed in each cluster identified in Fig. 4A. B GO pathways enriched among plasma proteins that exhibited decreased expression mainly COVID-19 non-ICU patient groups with respect to HD and COVID-19 ICU/F patientsanalysed in each cluster identified in Fig. 4A. C GO pathways enriched by plasma proteins that exhibited decreased expression in COVID-19 non-ICU and increased expression in COVID-19 ICU/F patients groups with respect to HDanalysed in each cluster identified in Fig. 4A. Top score processes obtained by the GO-based enrichment analysis (Fig. 3) are highlighted in red

Back to article page

Clinical Proteomics

ISSN: 1559-0275